ATE331039T1 - Feststellung von endometriumkrebs - Google Patents

Feststellung von endometriumkrebs

Info

Publication number
ATE331039T1
ATE331039T1 AT98909221T AT98909221T ATE331039T1 AT E331039 T1 ATE331039 T1 AT E331039T1 AT 98909221 T AT98909221 T AT 98909221T AT 98909221 T AT98909221 T AT 98909221T AT E331039 T1 ATE331039 T1 AT E331039T1
Authority
AT
Austria
Prior art keywords
endometrial cancer
detection
matrix metalloproteinase
assaying
qualitative
Prior art date
Application number
AT98909221T
Other languages
German (de)
English (en)
Inventor
Alexander Lopata
Lois A Salamonsen
Michael A Quinn
Original Assignee
Diagnotech Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Diagnotech Pty Ltd filed Critical Diagnotech Pty Ltd
Application granted granted Critical
Publication of ATE331039T1 publication Critical patent/ATE331039T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57442—Specifically defined cancers of the uterus and endometrial
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96486—Metalloendopeptidases (3.4.24)
    • G01N2333/96491—Metalloendopeptidases (3.4.24) with definite EC number
    • G01N2333/96494—Matrix metalloproteases, e. g. 3.4.24.7

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Food Science & Technology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Reproductive Health (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
AT98909221T 1997-03-20 1998-03-20 Feststellung von endometriumkrebs ATE331039T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AUPO5736A AUPO573697A0 (en) 1997-03-20 1997-03-20 Diagnosis of endometrial cancer

Publications (1)

Publication Number Publication Date
ATE331039T1 true ATE331039T1 (de) 2006-07-15

Family

ID=3800039

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98909221T ATE331039T1 (de) 1997-03-20 1998-03-20 Feststellung von endometriumkrebs

Country Status (14)

Country Link
US (1) US6607894B1 (enExample)
EP (1) EP0979304B1 (enExample)
JP (2) JP4183757B2 (enExample)
KR (1) KR20010006344A (enExample)
CN (1) CN1257550A (enExample)
AT (1) ATE331039T1 (enExample)
AU (1) AUPO573697A0 (enExample)
CA (1) CA2284099C (enExample)
DE (1) DE69835010T2 (enExample)
ES (1) ES2268767T3 (enExample)
MY (1) MY119567A (enExample)
NZ (1) NZ337868A (enExample)
WO (1) WO1998042865A1 (enExample)
ZA (1) ZA982403B (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6228596B1 (en) * 1998-03-05 2001-05-08 Diadexus, Inc. Method of detecting and monitoring endometrial and uterine cancers
AUPQ219799A0 (en) 1999-08-13 1999-09-02 R. Lurie Pty Ltd Apparatus for obtaining potological samples
US7071164B2 (en) 2001-08-16 2006-07-04 Kimberly-Clark Worldwide, Inc. Anti-cancer and wound healing compounds
US7186693B2 (en) 2001-08-16 2007-03-06 Kimberly - Clark Worldwide, Inc. Metalloproteinase inhibitors for wound healing
US7094754B2 (en) 2001-08-16 2006-08-22 Kimberly-Clark Worldwide, Inc. Anti-aging and wound healing compounds
US6906036B2 (en) 2001-08-16 2005-06-14 Kimberly-Clark Worldwide, Inc. Anti-aging and wound healing compounds
DE10217677A1 (de) 2002-04-19 2003-11-06 Bayer Ag Verwendung von Aufhellern zur Herstellung von Streichmassen
US7148194B2 (en) 2002-12-30 2006-12-12 Kimberly-Clark Worldwide, Inc. Method to increase fibronectin
US7189700B2 (en) 2003-06-20 2007-03-13 Kimberly-Clark Worldwide, Inc. Anti-chrondrosarcoma compounds
US20060003391A1 (en) * 2003-08-11 2006-01-05 Ring Brian Z Reagents and methods for use in cancer diagnosis, classification and therapy
US20050112622A1 (en) * 2003-08-11 2005-05-26 Ring Brian Z. Reagents and methods for use in cancer diagnosis, classification and therapy
ATE463743T1 (de) * 2004-07-23 2010-04-15 Ct De Rech Public De La Sante Überwachung von herzversagen
US20080131916A1 (en) * 2004-08-10 2008-06-05 Ring Brian Z Reagents and Methods For Use In Cancer Diagnosis, Classification and Therapy
RU2007133660A (ru) * 2005-02-09 2009-03-20 Дженентек, Инк. (Us) Ингибирование шеддинга her2 антагонистами матриксной металлопротеиназы
US7504225B2 (en) * 2005-05-12 2009-03-17 Applied Genomics, Inc. Reagents and methods for use in cancer diagnosis, classification and therapy
RU2304782C1 (ru) * 2005-12-28 2007-08-20 Государственное образовательное учреждение высшего профессионального образования Московская медицинская академия им. И.М. Сеченова Способ прогнозирования рецидива эндометриоидной кисты яичника
US8592393B2 (en) 2007-11-02 2013-11-26 Momenta Pharmaceuticals, Inc. Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization
US8569262B2 (en) 2007-11-02 2013-10-29 Momenta Pharmaceuticals, Inc. Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization
WO2009059284A2 (en) 2007-11-02 2009-05-07 Momenta Pharmaceuticals, Inc. Non-anticoagulant polysaccharide compositions
ES2458818T3 (es) * 2009-04-16 2014-05-07 Momenta Pharmaceuticals, Inc. Métodos para evaluar la actividad de una composición de polisacárido
EP2848700B1 (en) * 2009-07-24 2017-10-04 Geadic Biotec, AIE. Markers for endometrial cancer
CN102985443B (zh) 2010-04-16 2017-05-10 动量制药公司 组织靶向
RU2430371C1 (ru) * 2010-04-26 2011-09-27 Учреждение Российской академии наук Институт ядерной физики им. Г.И. Будкера Сибирского отделения РАН (ИЯФ СО РАН) Способ дифференциальной диагностики и прогноза миомы и рака эндометрия
US10017585B2 (en) 2010-06-17 2018-07-10 Momenta Pharmaceuticals, Inc. Methods and compositions for promoting hair growth
WO2012167163A2 (en) * 2011-06-03 2012-12-06 University Of South Alabama Methods and compositions for detecting endometrial or ovarian cancer
AU2012312071C1 (en) * 2011-09-22 2017-08-24 Memorial Sloan-Kettering Cancer Center Detecting ovarian cancer
SI2809801T1 (sl) * 2012-01-31 2018-12-31 SPEISER, Paul Neinvazivna diagnostika raka
EP3003324A4 (en) 2013-05-28 2017-01-25 Momenta Pharmaceuticals, Inc. Pharmaceutical compositions
US10564162B2 (en) * 2014-07-02 2020-02-18 Bionomics Limited Predictive biomarkers
MX381948B (es) * 2015-02-06 2025-03-13 Quest Diagnostics Invest Llc Composiciones y metodos para determinar el pronostico de cancer de endometrio.
BR112018072498A2 (pt) * 2016-05-04 2019-03-12 Fundacio Hospital Univ Vall Dhebron Institut De Recerca marcadores de câncer do endométrio
IN202021002695A (enExample) 2020-01-21 2021-07-23
CN112961921B (zh) * 2021-03-26 2022-07-01 中国医学科学院北京协和医院 一种用于判断早期子宫内膜癌预后的制剂及复发风险模型

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5280106A (en) * 1988-05-20 1994-01-18 Liotta Lance A Matrix metalloproteinase peptides: role in diagnosis and therapy
US5324634A (en) * 1992-03-31 1994-06-28 The Research Foundation Of State University Of New York Diagnostic tests measuring gelatinase/inhibitor complexes for detection of aggressive and metastatic cancer
WO1994005807A1 (en) * 1992-08-28 1994-03-17 Dickson Robert B Matrix-degrading metalloproteinase
EP0674710B1 (en) * 1992-11-16 2003-05-02 Cancer Research Fund Of Contra Costa Peptides with broad neoplastic specificity

Also Published As

Publication number Publication date
AUPO573697A0 (en) 1997-04-10
CN1257550A (zh) 2000-06-21
US6607894B1 (en) 2003-08-19
DE69835010T2 (de) 2007-06-06
MY119567A (en) 2005-06-30
EP0979304A1 (en) 2000-02-16
DE69835010D1 (de) 2006-08-03
JP2007202556A (ja) 2007-08-16
WO1998042865A1 (en) 1998-10-01
ZA982403B (en) 1998-10-21
CA2284099A1 (en) 1998-10-01
CA2284099C (en) 2010-04-27
EP0979304A4 (en) 2003-06-11
KR20010006344A (ko) 2001-01-26
ES2268767T3 (es) 2007-03-16
EP0979304B1 (en) 2006-06-21
JP2002501613A (ja) 2002-01-15
JP4183757B2 (ja) 2008-11-19
NZ337868A (en) 2002-05-31

Similar Documents

Publication Publication Date Title
ATE331039T1 (de) Feststellung von endometriumkrebs
ATE376187T1 (de) Nachweis von erkrankungen der nieren und behandlung
ATE241139T1 (de) Vorrichtung zur durchführung eines oder mehrerer kompetitiver immunoassays
ATE291583T1 (de) Polymorphismus von mononukleotiden und ihre verwendung in der genanalyse
FI953445A0 (fi) Menetelmä nukleiinihappojen herkkään osoitukseen
DK0941468T3 (da) Et-trins-hybridimmunochromatografisk udstyr og fremgangsmåde til anvendelse heraf
HK1040533A1 (zh) 监察蛋白脢体抑制剂药物活动的方法
DK0749325T3 (da) Bispecifikke molekyler med klinisk anvendelse
IL109817A0 (en) Improved method and analytical system for performing fibrinogen assays accurately, rapidly and simply
ES2186926T3 (es) Deteccion de la predisposicion genetica a la retinopatia diabetica amenazante de la vision.
ES2118062T3 (es) Composiciones reactivas, metodos y reactivos para la valoracion cuantitativa de magnesio o de calcio y magnesio.
ATE107705T1 (de) Test zur feststellung der empfänglichkeit für dns-assoziierte krankheiten.
FI946127A7 (fi) Menetelmä alukkeen pidentämiseksi yhdellä nukleotidilla spesifisten al leelien detektoimiseksi, ja testipakkaus näiden menetelmien suorittami seksi
ES516987A0 (es) Un procedimiento para la determinacion cuantitativa del factor xii de coagulacion de la sangre en el plasma sanguineo humano.
IL81695A (en) Quantitative determination of the degree of amplification of genes and/or corresponding messenger rna and reagent kit for performing the determination
NO953770L (no) Analysemetode
ATE384952T1 (de) Enzymhemmungsimmunverfahren
ES2175095T3 (es) Marcadores de adn respecto al tamaño de una camada de cerdos.
ES2154736T3 (es) Metodo de analisis.
ATE199025T1 (de) Test zur diagnose eines erhöhten brustkrebs- risikos
FI854627A7 (fi) Menetelmä ja reagenssi plasmassa, seerumissa tai kokoveressä olevan vapaan tyroksiinin kvantitatiiviseksi määrittämiseksi.
DK0791073T3 (da) Analysemetode
ATE213279T1 (de) Diagnoseverfahren und vorrichtung zum nachweis der prädisposition zu bestimmten krankheitszuständen, insbesondere osteoporose, auf basis von il-6 genpolymorphismus
EP1141703A4 (en) METHODS FOR DETERMINING INCREASED RISK FOR A WOMAN CARRYING A FETUS WITH DOWN SYNDROME
DE69632826D1 (de) Nukleinsaeure erkennung von hepatitis gb virus

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties